- Home
- MDGL
as 02-21-2025 4:00pm EST
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Upcoming Earnings Alert:
Get ready for potential market movements as Madrigal Pharmaceuticals Inc. MDGL prepares to release earnings report on 26 Feb 2025.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 7.1B | IPO Year: | N/A |
| Target Price: | $351.67 | AVG Volume (30 days): | 357.1K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -25.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $189.00 - $368.29 | Next Earning Date: | 02-26-2025 |
| Revenue: | $76,813,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 195.95% |
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Taub Rebecca | MDGL | Pres., R&D, and CMO | Jan 24 '25 | Sell | $335.24 | 648 | $217,235.52 | 456,662 | |
| Huntsman Carole | MDGL | Chief Commercial Officer | Jan 24 '25 | Sell | $335.24 | 347 | $116,328.28 | 10,438 | |
| Waltermire Robert E. | MDGL | Senior VP, Chief Pharma Dev. | Jan 24 '25 | Sell | $335.24 | 103 | $34,529.72 | 4,955 | |
| Sibold William John | MDGL | President and CEO | Jan 24 '25 | Sell | $335.24 | 1,584 | $531,020.16 | 54,303 | |
| Taub Rebecca | MDGL | Pres., R&D, and CMO | Jan 17 '25 | Sell | $273.41 | 1,689 | $461,789.49 | 456,662 | |
| Waltermire Robert E. | MDGL | Senior VP, Chief Pharma Dev. | Jan 17 '25 | Sell | $273.41 | 442 | $120,847.22 | 4,955 | |
| Kelley Shannon T | MDGL | General Counsel | Jan 17 '25 | Sell | $273.41 | 277 | $75,734.57 | 7,705 | |
| CRAVES FRED B | MDGL | Director | Dec 3 '24 | Sell | $315.56 | 3,600 | $1,135,121.70 | 11,000 | |
| CRAVES FRED B | MDGL | Director | Nov 25 '24 | Sell | $350.40 | 3,400 | $1,191,028.02 | 11,000 |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
GlobeNewswire
11 days ago
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 01/28/2025
MT Newswires
a month ago
Madrigal Pharmaceuticals Insider Sold Shares Worth $531,020, According to a Recent SEC Filing
Simply Wall St.
a month ago
Exploring Three High Growth Tech Stocks in the United States
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 01/21/2025
Motley Fool
a month ago
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
Zacks
a month ago
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
Compare MDGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.